Matches in DBpedia 2014 for { <http://dbpedia.org/resource/GW501516> ?p ?o. }
Showing items 1 to 50 of
50
with 100 items per page.
- GW501516 abstract "GW501516 (also known as GW-501,516, GW1516, GSK-516 and Endurobol) is a PPARδ receptor agonist that was previously investigated for drug use by GlaxoSmithKline. The drug was discovered to cause cancer in rats and GlaxoSmithKline has ceased development. It activates the same pathways activated through exercise, including PPARδ and AMP-activated protein kinase. It had been investigated as a potential treatment for obesity, diabetes, dyslipidemia and cardiovascular disease. GW501516 has a synergistic effect when combined with AICAR: the combination has been shown to significantly increase exercise endurance in animal studies more than either compound alone.".
- GW501516 atcPrefix "none".
- GW501516 casNumber "317318-70-0".
- GW501516 chEBI "73726".
- GW501516 iupacName "{4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]-2-methylphenoxy}acetic acid".
- GW501516 pubchem "9803963".
- GW501516 thumbnail Gw501516.svg?width=300.
- GW501516 wikiPageID "16366361".
- GW501516 wikiPageRevisionID "605727167".
- GW501516 atcPrefix "none".
- GW501516 c "21".
- GW501516 casNumber "317318".
- GW501516 chebi "73726".
- GW501516 chembl "38943".
- GW501516 chemspiderid "7979723".
- GW501516 f "3".
- GW501516 h "18".
- GW501516 iupacName "{4-[sulfanyl]-2-methylphenoxy}acetic acid".
- GW501516 iupharLigand "2687".
- GW501516 legalAu "unscheduled".
- GW501516 legalUk "unscheduled".
- GW501516 legalUs "unscheduled".
- GW501516 molecularWeight "453.498".
- GW501516 n "1".
- GW501516 o "3".
- GW501516 pregnancyCategory "N/A".
- GW501516 pubchem "9803963".
- GW501516 routesOfAdministration "oral".
- GW501516 s "2".
- GW501516 smiles "O=CO".
- GW501516 stdinchi "1".
- GW501516 stdinchikey "YDBLKRPLXZNVNB-UHFFFAOYSA-N".
- GW501516 tradename "Endurobol".
- GW501516 verifiedfields "changed".
- GW501516 verifiedrevid "458657924".
- GW501516 subject Category:Drugs.
- GW501516 subject Category:GlaxoSmithKline.
- GW501516 subject Category:PPAR_agonists.
- GW501516 type Drug.
- GW501516 type FunctionalSubstance.
- GW501516 comment "GW501516 (also known as GW-501,516, GW1516, GSK-516 and Endurobol) is a PPARδ receptor agonist that was previously investigated for drug use by GlaxoSmithKline. The drug was discovered to cause cancer in rats and GlaxoSmithKline has ceased development. It activates the same pathways activated through exercise, including PPARδ and AMP-activated protein kinase. It had been investigated as a potential treatment for obesity, diabetes, dyslipidemia and cardiovascular disease.".
- GW501516 label "GW501516".
- GW501516 label "GW501516".
- GW501516 sameAs GW501516.
- GW501516 sameAs m.03whwrd.
- GW501516 sameAs Q5515069.
- GW501516 sameAs Q5515069.
- GW501516 wasDerivedFrom GW501516?oldid=605727167.
- GW501516 depiction Gw501516.svg.
- GW501516 isPrimaryTopicOf GW501516.
